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Abstract
Background: Cardiomyocyte calcium overloading has been implicated in the pathogenesis of Duchenne muscular
dystrophy (DMD) heart disease. The cardiac isoform of sarcoplasmic reticulum calcium ATPase (SERCA2a) plays a
major role in removing cytosolic calcium during heart muscle relaxation. Here, we tested the hypothesis that
SERCA2a over-expression may mitigate electrocardiography (ECG) abnormalities in old female mdx mice, a murine
model of DMD cardiomyopathy.
Methods: 1×1 0
12 viral genome particles/mouse of adeno-associated virus serotype-9 (AAV-9) SERCA2a vector was
delivered to 12-m-old female mdx mice (N = 5) via a single bolus tail vein injection. AAV transduction and the ECG
profile were examined eight months later.
Results: The vector genome was detected in the hearts of all AAV-injected mdx mice. Immunofluorescence
staining and western blot confirmed SERCA2a over-expression in the mdx heart. Untreated mdx mice showed
characteristic tachycardia, PR interval reduction and QT interval prolongation. AAV-9 SERCA2a treatment corrected
these ECG abnormalities.
Conclusions: Our results suggest that AAV SERCA2a therapy may hold great promise in treating dystrophin-
deficient heart disease.
Background
The heart is often afflicted in Duchenne muscular dys-
trophy (DMD), a lethal muscle disease caused by dystro-
phin deficiency (reviewed in [1]). Dystrophin is a large
sub-sarcolemmal protein that plays a critical role in
maintaining sarcolemma integrity. In a dystrophin-defi-
cient heart, myocardial contraction results in sarcolem-
mal damage. Subsequent cardiomyocyte necrosis and
fibrosis leads to dilated cardiomyopathy. The exact
molecular mechanisms underlying dystrophin-deficient
heart disease remain to be fully clarified. Interestingly,
ample evidence suggests that abnormal elevation of
cytosolic calcium may play a central role in the patho-
genesis of DMD heart disease [2-6].
The sarcoplasmic reticulum is the primary calcium
storage organelle in muscle cells. In cardiomyocytes,
removal of cytosolic calcium is mainly accomplished by
the cardiac isoform of sarcoplasmic reticulum calcium
ATPase (SERCA2a) via its pump activity (reviewed in
[7]). Basically, SERCA2a actively transports calcium
from the cytosol to the sarcoplasmic reticulum during
myocardial relaxation. SERCA2a expression/activity is
reduced in various forms of heart failure in experimental
animal models and human patients (reviewed in [8,9]).
In the heart of dystrophin-deficient mdx mice, SERCA2a
expression is also significantly decreased [10]. Here, we
hypothesize that intentional SERCA2a over-expression
may help mitigate cytosolic calcium overload and
improve cardiac electrophysiology in symptomatic mdx
mice.
Among various gene transfer vectors, adeno-associated
virus serotype-9 (AAV-9) is by far the most robust vec-
tor for transducing the mdx heart when administrated
intravascularly [11-13]. We have recently established the
aged female mdx mice as an authentic model of DMD
cardiomyopathy [14,15]. To test our hypothesis, we
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12 viral genome (vg) particles/mouse of
AAV-9 SERCA2a vector to 12-m-old female mdx mice
via a single bolus tail vein injection. Electrocardiography
(ECG) was performed when mice reached 20 months of
age. Compared to that of age- and gender-matched
untreated mdx mice, the ECG profile of AAV-9 SER-
CA2a treated mdx mice was significantly improved.
Methods
Recombinant AAV-9 SERCA2a vector
The cis plasmid for AAV-9 SERCA2a vector production
has been extensively characterized and used in various
animal studies and human trials [16-19]. In this con-
struct, the human SERCA2a cDNA expression was regu-
lated by the ubiquitous cytomegalor virus (CMV)
promoter, a hybrid intron and a bovine growth hormone
poly-adenylation signal (Figure 1A). Experimental AAV
vector was produced using a previously reported triple
plasmid transfection protocol [20,21]. Recombinant viral
stocks were purified through two rounds of isopycnic
CsCl ultracentrifugation as we previously described [22].
Viral titration and quality control were performed
according to our published protocol [22,23].
In vivo gene delivery
All animal experiments were approved by the Animal
Care and Use Committee of the University of Missouri
and were in accordance with NIH guidelines. Dystro-
phin-deficient mdx mice and normal control C57Bl/10
(BL10) mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME). AAV-9 SERCA2a vector was
injected to conscious 12-m-old mdx mice in a single
bolus through the tail vein according to a previously
described protocol [11]. Each mouse received 1 × 10
12
vg particles of AAV-9.
PCR detection of the AAV vector genome
DNA was extracted from frozen heart tissue sections as
we described before [24]. The AAV SERCA2a vector
genome was amplified with a forward primer corre-
sponding to the CMV promoter (DL1263, 5’-CCAAG-
TACGCCCCCTATTGA) and a reverse primer
corresponding to the human SERCA2a cDNA (DL1262,
5’- AGCCCCGTACTCTCGTTGAC) (Figure 1A). The
size of the expected PCR product is 519 bp. The mouse
CFTR gene was used as an internal control. The forward
primer corresponds to the mouse cystic fibrosis trans-
membrane conductance regulator (CFTR) gene exon 2
(DL1286, 5’-CATATACCAAGCCCCTTCTGCT). The
reverse primer corresponds to the mouse CFTR gene
intron 2 (DL1287, 5’- TGCATCACTTTTAAATG-
GAACCTC). The expected mouse CFTR gene amplicon
size is 160 bp.
Western blot
The frozen heart was ground to fine powder in liquid
nitrogen. Whole heart muscle lysate was prepared
according to our published protocol [15,25]. Primary
antibody of for SERCA2a (1:3,000) has been previously
described [26]. A monoclonal antibody to b-actin
(1:5,000, Sigma; St Louis, MO) was used to confirm pro-
tein loading.
SERCA2a immunofluorescence staining
SERCA2a expression was confirmed by immunofluores-
cence staining. Briefly, 10 μm frozen heart sections was
blocked with 20% goat serum at room temperature for
30 min. The rabbit polyclonal anti-SERCA2a antibody
was then applied at the dilution of 1:3,000 overnight at
4°C [26]. SERCA2a staining was revealed with an Alex
488 conjugated goat anti-rabbit antibody (1:100
dilution).
Histopathology examination
General heart histology was evaluated by hematoxylin
and eosin (HE) staining. Cardiac fibrosis was examined
by Masson trichrome staining as we described before
[27]. Fibrotic tissue stained blue and myocardium
stained dark red.
ECG examination
Mice were anesthetized with isoflurane (3% induction,
1-1.5% maintenance). A non-invasive 12-lead ECG was
performed according to our published protocol [28].
ECG signals were processed through a single channel
bioamplifier (Model ML132; AD Instruments) and then
recorded on a Model MLA0112S PowerLab system
using the Chart software (version 5.5.5, AD Instruments,
Colorado Springs, CO). ECG from a continuous 1 min
recording was analyzed by the Chart ECG analysis soft-
ware (version 2.0, AD Instruments). The amplitude of
the Q wave was analyzed using the lead I tracing. The
remaining ECG parameters were analyzed using lead II
tracing results. Cardiomyopathy index is determined by
dividing the QT interval with the PQ segment (QT/PQ).
Statistical Analysis
Data are presented as mean ± standard error of mean.
Statistical analysis was performed with the SPSS soft-
ware (SPSS, Chicago, IL) using one-way ANOVA fol-
lowed by Bonferroni post hoc analysis. Difference was
considered significant when P < 0.05.
Results
AAV-9 mediated SERCA2a gene transfer in old mdx mice
To evaluate SERCA2a gene therapy in a dystrophin-defi-
cient heart, we packaged theC M V . S E R C A 2 ac o n s t r u c t
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Page 2 of 7Figure 1 AAV-9 mediated SERCA2a transduction in the mdx heart. A, Schematic outline of the AAV SERCA2a vector used in the study. The
human SERCA2a cDNA is driven by the CMV promoter. i, intron. Arrows mark the locations of the PCR primers. B, PCR detection of the AAV
SERCA2a vector genome in the mdx heart. Pos. Ctrl., the SERCA2a cis plasmid; Uninf., from an uninfected mdx heart; #1 to #5, from five AAV-9
SERCA2a vector infected mdx mouse hearts. Each line represents PCR result from one mouse; H2O, no DNA was added in the PCR reaction.
Arrowhead, the 519 bp diagnostic band for the AAV SERCA2a genome; Arrow, the 160 bp diagnostic band for the CFTR gene (internal control).
C, Representative SERCA2a western blot. b-actin was used as the loading control. D, Representative SERCA2a immunofluorescence staining
images from BL10, mdx and AAV-9 SERCA2a infected mdx hearts. Enlarged images (bottom panels) are the boxed areas from the corresponding
low-power photomicrographs (top panels). Asterisk, AAV SERCA2a transduced cardiomyocytes.
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mice is mildly affected, we opted to test SERCA2a ther-
apy in 12-month-old mdx mice [29]. At this age, mdx
mice exhibit cardiac histopathology but do not suffer
heart failure [29]. The CMV.SERCA2a vector has been
extensively characterized in different animal models and
is currently in use in a human trial [17-19,30,31]. We
injected AAV-9 SERCA2a to 12-m-old mdx mice via
the tail vein. Eight months later, we examined the AAV
genome in the heart. The vector genome was detected
in all mdx mice that received AAV-9 SERCA2a injection
but not in untreated mdx mice (Figure 1B). To confirm
SERCA2a expression, we performed western blot and
immunofluorescence staining. Compared with untreated
mdx, increased SERCA2a expression was found in AAV
infected mdx mice by western blot (Figure 1C). Consis-
tent with previous reports [10,32], we observed endo-
genous cytosolic SERCA2a staining in the BL10 heart by
immunostaining (Figure 1D). Further, the endogenous
SERCA2a level was reduced in the mdx heart (Figure
1D). Consistent with the published AAV-9 transduction
profile in the mdx heart [11,12], we observed mosaic
but widespread AAV-mediated SERCA2a expression in
the hearts of AAV-9 SERCA2a infected mdx mice (Fig-
ure 1D).
AAV-9 SERCA2a therapy improved ECG performance
On histopathologic examination, the hearts of SERCA2a
treated mice were not different from those of untreated
mdx mice (Figure 2). Myocardial fibrosis was clearly
observed in the hearts of both treated and untreated
mdx mice (Figure 2). Surprisingly, ECG examination
revealed significant improvement (Figure 3). Specifically,
tachycardia was corrected. The PR interval, QT interval
and cardiomyopathy index were normalized (Figure 3B).
Interestingly, the widened QRS duration and the deep Q
wave were not improved (Figure 3B).
Discussion
Cardiac complications are a major health issue in DMD.
Current treatments are limited to symptomatic medica-
tions and heart transplantation [33]. In an effort to
develop more effective therapies, several experimental
gene therapy approaches have been explored in the
rodent models [29]. These include AAV-mediated
expression of an abbreviated synthetic dystrophin gene
and antisense oligonucleotides-mediated exon skipping
[12,13,34-36]. In general, the goal of these strategies is
to express a truncated yet functional dystrophin protein.
While these attempts are highly encouraging, a recent
clinical trial suggests that immunity to dystrophin may
BL10 Uninfected Mdx
AAV.SERCA2a 
Infected Mdx
H
E
M
a
s
s
o
n
 
T
r
i
c
h
r
o
m
e
μ
Figure 2 SERCA2a expression does not mitigate histological lesions in the mdx heart. Top panels, representative HE staining images;
Bottom panels, representative Masson trichrome staining images.
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based on endogenous genes may offer immune advan-
tages compared to dystrophin replacement/repair
therapies.
Over the last decade tremendous progress has been
made in our understanding of the pathogenesis of DMD
cardiomyopathy. An emerging theme is the disruption
of calcium homeostasis (reviewed in [38,39]). First,
stress-induced calcium influx is significantly increased in
mdx cardiomyocytes. Extracellular calcium may enter
through stretch-activated calcium channel (such as
TRPC1), sarcolemmal microrupture and sodium-calcium
exchanger [4,40,41]. Second, calcium may leak from the
sarcoplasmic reticulum via phosphorylated and/or S-
nitrosylated ryanodine receptor 2 [5,6]. Collectively,
these studies suggest that calcium overloading may
represent a major pathogenic mechanism in DMD heart
disease. Since SERCA2a plays a major role in calcium
removal in the heart, we reasoned that forced expression
of SERCA2a via AAV gene transfer might benefit dys-
trophin-deficient heart. We observed AAV genome per-
sistence and SERCA2a over-expression in the hearts of
20-m-old mdx mice that were treated at age of 12
months (Figure 1). In support of our hypothesis, the
ECG profile was significantly improved in AAV SER-
CA2a treated mice (Figure 3).
AAV SERCA2a therapy has successfully reversed car-
diac dysfunction in several large animal models
[17,30]. A Phase I trial has revealed an excellent safety
profile [18,19]. Recently released results from the
Phase II trail have further established clinical efficacy
of AAV SERCA2a therapy in treating advanced heart
failure [31]. While additional in vitro analysis of myo-
cardial contractility and in vivo evaluation of hemody-
namics (echocardiography and cardiac catheter) are
needed [42], our results demonstrate for the first time
that AAV SERCA2a may hold great promise in alle-
viating cardiac disease in DMD patients. Consistent
with our findings in the heart, a recent study suggests
that AAV SERCA2a also significantly reduced skeletal
muscle disease in dystrophic mice following local gene
transfer [43].
Conclusions
Our results here have opened a new avenue to treat
DMD cardiomyopathy using AAV SERCA2a gene deliv-
ery. Future studies in aged mdx mice, dystrophin/utro-
phin double knockout mice and dystrophin-deficient
Figure 3 AAV-9 SERCA2a expression improves the ECG profile in mdx mice. A, Representative single lead II tracings from BL10, mdx and
AAV SERCA2a treated mdx mice. PR, the time interval between the onset of atrial depolarization and the onset of ventricular depolarization. B,
Quantitative evaluation of ECG profiles in BL10, mdx, AAV SERCA2a treated mdx mice. *, Statistically different from other groups. HR, heart rate;
PR, PR interval; QRS, QRS duration; QT, QT interval; Q Amp, Q amplitude in lead I; C. Index, cardiomyopathy index.
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therapy for DMD.
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